Does GLP-1 Work Differently for Men vs Women?

Introduction

GLP-1 medications work in both sexes, but the response pattern differs. In the STEP 1 trial (Wilding et al. 2021 NEJM), women lost an average of 17.3% of body weight on semaglutide 2.4 mg, while men lost 12.9%. Women generally show higher percentage weight loss. Men typically show greater absolute pound loss and more visceral fat reduction.

Several biological factors explain the gap. Women have higher endogenous GLP-1 secretion, lower lean body mass relative to fat mass, and estrogen-mediated effects on appetite regulation. Men carry more visceral adipose tissue at baseline, so they have more of it to lose.

The clinical bottom line: dosing, titration, and target weight goals should not be set by sex alone. They depend on starting BMI, comorbidities, and tolerability.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why Do Women Lose More Weight on GLP-1?

Women typically lose a higher percentage of body weight on semaglutide and tirzepatide than men do in randomized trials. The STEP program (semaglutide) and SURMOUNT program (tirzepatide) both replicated this pattern across multiple sub-studies.

Quick Answer: In STEP 1, women lost 17.3% body weight vs 12.9% for men on semaglutide 2.4 mg

Several mechanisms contribute. Estrogen enhances GLP-1 receptor signaling in the hypothalamus, which amplifies appetite suppression. Women also have a higher fat mass percentage at any given BMI, leaving more adipose tissue available for loss. And the typical female caloric maintenance is lower, so a fixed appetite reduction creates a larger relative deficit.

Men still lose meaningful weight, just at a lower percentage. A 250-pound man losing 13% loses 32 pounds. A 200-pound woman losing 17% loses 34 pounds. The absolute numbers can match even when the percentages diverge.

Do Men Lose More Visceral Fat on GLP-1?

Yes. Men tend to lose more visceral adipose tissue (VAT) in absolute terms because they carry more of it. MRI substudies from SURMOUNT-1 showed tirzepatide reduced VAT by roughly 33% in men versus 28% in women at 72 weeks, though women started with less VAT to lose.

Visceral fat is the metabolically dangerous depot wrapped around organs. Reducing it improves insulin sensitivity, liver fat, and cardiovascular risk markers faster than reducing subcutaneous fat does. For men with metabolic syndrome, this preferential VAT loss is a major clinical win.

Women see proportionally larger reductions in subcutaneous fat, particularly in the hips and thighs. Both patterns improve overall body composition.

Are Side Effects Different Between Men and Women?

Women report nausea, vomiting, and constipation at slightly higher rates than men on GLP-1 medications. STEP 1 pooled data showed about 44% of women experienced nausea versus 38% of men on semaglutide 2.4 mg. The reasons aren’t fully understood but likely involve hormonal modulation of gastric emptying.

Severe adverse events occur at similar rates between sexes. The discontinuation rate due to GI side effects is around 7% in both groups in the STEP and SURMOUNT trials.

One sex-specific consideration: women of reproductive age must use contraception on tirzepatide, particularly during dose changes, because GLP-1 receptor agonists can reduce the effectiveness of oral contraceptives during gastric emptying delays.

Does GLP-1 Affect Hormones Differently by Sex?

GLP-1s improve insulin sensitivity and reduce androgens in women with PCOS, often restoring ovulation and regular menstrual cycles. This is a documented secondary benefit, not an off-label experiment. Several small trials show semaglutide reduces free testosterone and improves menstrual regularity in PCOS within 6 months.

In men, GLP-1 weight loss tends to raise testosterone levels modestly. Obesity suppresses testosterone through aromatization of androgens to estrogens in adipose tissue. As fat mass drops, free testosterone often rises 15-25% based on observational data, particularly in men with baseline hypogonadism related to obesity.

Neither effect requires special dosing changes, but both are worth monitoring if relevant.

Should Men or Women Dose Differently?

No. Standard titration applies regardless of sex. Semaglutide starts at 0.25 mg weekly and titrates up monthly to a max of 2.4 mg. Tirzepatide starts at 2.5 mg weekly and titrates to 5, 7.5, 10, 12.5, or 15 mg based on tolerability and response.

The decision to go higher or stay lower depends on weight loss progress, side effects, and goals. A woman who hits target weight on 1.7 mg semaglutide has no reason to push to 2.4 mg. A man who is still losing 1% per month on 5 mg tirzepatide can hold there.

Personalized titration matters more than sex-based dosing rules. A free assessment quiz with TrimRx pairs your medical history with a recommended starting dose and titration plan.

Key Takeaway: Men lose more visceral fat in absolute terms; women lose higher percentage of total weight

Does Menopause Change GLP-1 Response?

Limited but suggestive data. Post-menopausal women in STEP and SURMOUNT subgroup analyses showed slightly lower percentage weight loss than pre-menopausal women, though still substantially more than men in the same trials.

Loss of estrogen reduces the hormonal amplification of GLP-1 signaling, which may explain the small drop in response. Post-menopausal women also tend to gain visceral fat at higher rates, so the metabolic benefits of GLP-1 can be especially meaningful in this group.

Hormone replacement therapy doesn’t appear to interfere with GLP-1 efficacy in available observational data, but the trials weren’t designed to answer that question.

Are Cardiovascular Benefits the Same for Men and Women?

The SELECT trial (Lincoff et al. 2023 NEJM) found semaglutide reduced major adverse cardiovascular events (MACE) by 20% in adults with overweight or obesity and established heart disease. The benefit was statistically consistent across sex subgroups, though men had higher absolute event rates at baseline.

The FLOW trial (Perkovic et al. 2024 NEJM) showed a 24% reduction in kidney disease progression or cardiovascular death with semaglutide in type 2 diabetes patients with chronic kidney disease. Sex did not significantly modify the treatment effect.

Both sexes get the cardio-protective and renal-protective benefits, even when weight loss differences exist.

Do Exercise and Diet Effects Differ by Sex on GLP-1?

Strength training preserves lean mass during weight loss, and this matters more for women than men proportionally. Women lose lean mass at higher rates during caloric deficit due to lower baseline muscle mass. Adding 2-3 resistance sessions per week on GLP-1 protects against sarcopenic obesity.

Protein intake targets are similar for both sexes: 1.2-1.6 g per kg of body weight daily during weight loss. Many women under-eat protein at baseline, so the increase requires more conscious effort.

Cardio improves cardiovascular fitness and helps maintain weight loss but doesn’t drive most of the body composition wins. Strength training does.

Bottom line: Same titration schedule applies regardless of sex

FAQ

Do Women Regain Weight Faster Than Men After Stopping GLP-1?

Both sexes regain about two-thirds of lost weight within a year of stopping, per the STEP 1 extension data. Sex did not significantly modify the regain rate.

Is GLP-1 Effective for PCOS?

Yes. Multiple small trials show semaglutide and tirzepatide reduce insulin resistance, lower androgens, and restore ovulation in women with PCOS. It is increasingly used off-label for this purpose.

Should Pregnant Women Take GLP-1?

No. GLP-1 medications are contraindicated in pregnancy and should be stopped at least 2 months before conception with semaglutide and 1 month with tirzepatide.

Does Testosterone Replacement Therapy Interact with GLP-1?

No known direct interaction. Men on TRT can take semaglutide or tirzepatide safely. Weight loss can improve endogenous testosterone production over time.

Why Do Men Lose More Pounds but Women Lose More Percentage?

Men typically weigh more at baseline, so 13% of a larger number can equal or exceed 17% of a smaller one in absolute pounds. Percentage loss is the more meaningful clinical metric.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.